LATASHA CLAIBORNE: Open Payments
NPI 1104104413 · VICKSBURG, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$550 in 26 payments from 8 companies in 2025. Trend: 2023 $301 · 2024 $637 · 2025 $550
Food & beverage: $550
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 5 | $133 |
| Vanda Pharmaceuticals Inc. | 5 | $119 |
| Neurocrine BioSciences, Inc. | 4 | $79 |
| Alkermes, Inc. | 3 | $66 |
| Axsome Therapeutics, Inc. | 3 | $50 |
| E.R. Squibb & Sons, L.L.C. | 2 | $38 |
| Lundbeck LLC | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 2 | $30 |
Products named: VRAYLAR, FANAPT, INGREZZA, REXULTI, Auvelity, COBENFY, ARISTADA, LYBALVI.
Industry payments across MS — which companies pay providers there.
